Mechanistic understanding of what sleep is for
Knowing which restorative functions sleep performs and whether they can be satisfied in less time, or by other means, without long-term harm.
State of the art
DEC2/BHLHE41 P385R (2009) and ADRB1 A187V (2019) familial natural short sleep mutations reduce sleep in carriers and in knock-in mice without obvious deficit; candidate functions (glymphatic clearance, synaptic downscaling) remain unresolved.
- No consensus on sleep's core function, so no way to verify a shortened-sleep design is not accruing damage
- No biomarker of sleep debt, so safety can only be assessed by lifetime outcome studies
- Known short-sleeper families are tiny cohorts with no controlled long-term follow-up
Who’s working on it
- Ying-Hui FuResearcherUniversity of California, San Francisco
Identified the familial natural short sleep genes, five so far, and showed short-sleep alleles reduce dementia-linked aggregates in mouse models
- Louis PtacekResearcherUniversity of California, San Francisco
Co-leads the short-sleeper family cohort work with Fu, including the 2019 ADRB1 A187V discovery
- Maiken NedergaardResearcherUniversity of Rochester and University of Copenhagen
Showed norepinephrine-driven slow vasomotion pumps glymphatic clearance during sleep and that zolpidem suppresses it (Cell, January 2025)
- Giulio TononiResearcherUniversity of Wisconsin-Madison
With Chiara Cirelli, authored the synaptic homeostasis hypothesis, the main rival account of sleep's function, still being tested ultrastructurally in 2025
- Chiara CirelliResearcherUniversity of Wisconsin-Madison
Co-principal investigator of the Wisconsin sleep and consciousness lab doing the electron-microscopy work on synapse renormalisation during sleep
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Deep longitudinal phenotyping of familial short-sleeper cohorts and knock-in primates, with cognitive, metabolic and neurodegeneration endpoints | $$ $10M – $100M |
| research | Candidate sleep-debt biomarker discovery (CSF clearance, synaptic turnover markers) usable in awake humans | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.
Required by
No other capability builds on this directly.